Search Results - "Maslak, P. G."

A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease by Maslak, P G, Dao, T, Gomez, M, Chanel, S, Packin, J, Korontsvit, T, Zakhaleva, V, Pinilla-Ibarz, J, Berman, E, Scheinberg, D A

Get full text

Monoclonal antibody therapy of APL by Maslak, P G, Jurcic, J G, Scheinberg, D A

“…Acute promyelocytic leukemia (APL) is a rare subtype of acute myeloid leukemia (AML) for which a number of targeted therapies have been developed. The…”
Get more information

Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia by Maslak, P G, Weiss, M A, Berman, E, Yao, T J, Tyson, D, Golde, D W, Scheinberg, D A

“…Given the high treatment-related mortality in elderly patients with acute myelogenous leukemia (AML), we undertook a study using granulocyte colony-stimulating…”
Get more information

Chronic myelomonocytic leukemia (CMML) associated with symptomatic pericardial effusion by Ibrahim, M. I., Maslak, P. G., Heaney, M. L., George, M. S., Downey, R. J., Tallman, M. S.

“…Abstract only…”
Get full text

Decitabine for the treatment of acute myeloid leukemia (AML): Memorial Sloan-Kettering Cancer Center experience by Ganetsky, A., Adel, N. G., Frattini, M. G., Maslak, P. G., Heaney, M. L., Jurcic, J. G., Tallman, M. S.

“…Abstract only…”
Get full text

Randomized, double-blinded, phase II trial of a WT1 peptide vaccine as adjuvant therapy in patients with malignant pleural mesothelioma (MPM) by Krug, L. M., Tsao, A. S., Kass, S., Rusch, V. W., Travis, W. D., Panageas, K., Adusumili, P. S., Kris, M. G., Maslak, P. G., Scheinberg, D. A.

“…Abstract only…”
Get full text

Arsenic trioxide followed by autologous stem cell transplant for patients with relapsed APL by Shepard, D. D., Kohrt, H. E., Rosenblat, T. L., Jurcic, J. G., Park, J. H., Goldman, A., Dalal, J. S., Maslak, P. G., Jakubowski, A. A., Klimek, V., Berman, E., Nand, S., Coutre, S. E., Tallman, M. S., Erba, H. P.

“…Abstract only…”
Get full text

Cytomorphologic and clinical features of AML with translocation (8;16) mimicking APL by Jhanwar, S., Diab, A., Zickl, L., Manji, G. A., Patel, J., Abdel-Wahab, O. I., Jurcic, J. G., Maslak, P. G., Steinherz, P. G., Paietta, E., Feldstein, J., Levine, R. L., Tallman, M. S.

“…Abstract only…”
Get full text

Pharmacokinetics (PK) and pharmacodynamics (PD) of RG7112, an oral murine double minute 2 (MDM2) antagonist, in patients with leukemias and solid tumors by Beryozkina, A., Nichols, G. L., Reckner, M., Vassilev, L. T., Rueger, R., Jukofsky, L., Middleton, S., Andreeff, M., Padmanabhan, S., Strair, R., Delioukina, M. L., Maslak, P. G., Hillmen, P., Kurzrock, R., Gore, L., Patnaik, A., Maki, R. G., Schwartz, G. K., Wagner, A. J., Zhi, J.

“…Abstract only…”
Get full text

Refractory aspergillus pneumonia in patients with acute leukemia: Successful therapy with combination caspofungin and liposomal amphotericin by ALIFF, Timothy B, MASLAK, Peter G, JURCIC, Joseph G, HEANEY, Mark L, CATHCART, Kathleen N, SEPKOWITZ, Kent A, WEISS, Mark A

“…Pulmonary aspergillosis and other invasive fungal infections (IFIs) commonly complicate the management of patients with acute leukemia. Standard…”
Get full text

Pilot trial of a synthetic breakpoint peptide vaccine in patients with chronic myeloid leukemia (CML) and minimal disease by Maslak, P. G., Dao, T., Gupta, S., Gomez, M., Chanel, S., Korontsvit, T., Zakhaleva, V., Ashraf, S., Berman, E., Scheinberg, D.

“…Abstract only 6514 Background: CML is characterized by a tumor-specific fusion oncoprotein, BCR-ABL. Peptides spanning the B3A2 breakpoint of BCR-ABL can…”
Get full text

Pentostatin and Cyclophosphamide: An Effective New Regimen in Previously Treated Patients With Chronic Lymphocytic Leukemia by WEISS, Mark A, MASLAK, Peter G, JURCIC, Joseph G, SCHEINBERG, David A, ALIFF, Timothy B, LAMANNA, Nicole, FRANKEL, Stanley R, KOSSMAN, Steven E, HORGAN, Denise

“…Purine analogs and alkylators are important agents in the treatment of chronic lymphocytic leukemia (CLL). Previously, combinations of fludarabine and…”
Get full text

A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia by Weiss, Mark A., Aliff, Timothy B., Tallman, Martin S., Frankel, Stanley R., Kalaycio, Matt E., Maslak, Peter G., Jurcic, Joseph G., Scheinberg, David A., Roma, Todd E.

“…BACKGROUND The majority of adult patients who are treated for lymphoblastic disease will either develop recurrent disease or will be refractory to their…”
Get full text